CLRB — Cellectar Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $113.23m
- $103.67m
Annual cashflow statement for Cellectar Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -14.1 | -15.1 | -24.1 | -28.6 | -38 |
| Depreciation | |||||
| Non-Cash Items | 0.88 | 0.349 | 1.2 | 1.55 | 1.94 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.39 | 0.671 | 0.199 | 1.68 | 3.48 |
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -11.7 | -13.9 | -22.6 | -25.2 | -32.4 |
| Capital Expenditures | -0.025 | -0.062 | -0.141 | -0.226 | -0.864 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | — | — | — | — |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -0.025 | -0.062 | -0.141 | -0.226 | -0.864 |
| Financing Cash Flow Items | 0 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 9.02 | 60.5 | 1.25 | 9.61 | 22.9 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -2.7 | 46.6 | -21.5 | -15.8 | -10.3 |